ロード中...
AXL mediates resistance to cetuximab therapy
The EGFR antibody cetuximab is used to treat numerous cancers, but intrinsic and acquired resistance to this agent is a common clinical problem. In this study we show that overexpression of the oncogenic receptor kinase AXL is sufficient to mediate acquired resistance to cetuximab in models of non-s...
保存先:
| 主要な著者: | , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4167493/ https://ncbi.nlm.nih.gov/pubmed/25136066 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-14-0294 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|